TY - DATA T1 - Biocore analysis of cilostazol-PDE3B/Epac-1 interaction. PY - 2015/07/16 AU - Ayako Hashimoto AU - Michinori Tanaka AU - Satoshi Takeda AU - Hideki Ito AU - Keisuke Nagano UR - https://plos.figshare.com/articles/figure/_Biocore_analysis_of_cilostazol_PDE3B_Epac_1_interaction_/1485819 DO - 10.1371/journal.pone.0132835.g007 L4 - https://ndownloader.figshare.com/files/2179035 KW - haec KW - pka KW - protein kinase KW - induction effect KW - MAPK Activation KW - pi KW - Cilostazol Induces PGI 2 Production KW - 3k KW - intracellular calcium KW - Culture media KW - phospholipase C KW - cyclic AMP 1 KW - intracellular calcium elevation KW - Human Aortic Endothelial Cells BackgroundCilostazol KW - phosphodiesterase 3 KW - PDE 3B KW - PGI 2 synthesis KW - plc KW - intracellular cAMP accumulation KW - exchange protein KW - ResultsHuman aortic KW - arachidonic acid pathway KW - ischemic diseases KW - PGI 2 accumulation N2 - (A) Cilostazol, cilostamide, and milrinone interfere with association of PDE3B-binding Epac-1 peptides-1 to PDE3B. The above-mentioned compounds’ competition with PDE3B-binding Epac-1 peptides-1 (5 μM) binding to Epac-1-binding PDE3B peptide was evaluated (n = 4; ** p < 0.01 vs. 5 μM PDE3B-binding Epac-1 peptides-1, randomized Dunnett’s test). (B) Cilostazol, cilostamide, and milrinone interfere with association of PDE3B-binding Epac-1 peptides-2 to PDE3B. These compounds’ competition with Epac-1 peptides-2 (5 μM) binding to Epac-1-binding PDE3B peptide was evaluated (n = 4; * p < 0.05, ** p < 0.01 vs. 5 μM PDE3B-binding Epac-1 peptides-2, randomized Dunnett’s test). (C) Direct bindings of cilostazol, cilostamide, and milrinone to PI3Kγ-binding PDE3B peptide. Relative responses of PI3Kγ-binding PDE3B peptide to drugs at concentrations of 0.3125, 0.625, 1.25, 2.5, and 5 μM (n = 4). ER -